First oral small molecule CGRP receptor inhibitor approved today for the treatment of migraine
Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related peptide (CGRP) receptor antagonist Ubrelvy (Ubrogepant) developed by Allergan for the acute treatment of migraine. This is the first FDA-approved oral CGRP receptor antagonist and represents a new type of drug for this stubborn disease.As a result, Ubrogepant became the first oral CGRP inhibitor drug in the United States for the acute treatment of migraine (with or without aura) for more than 25 years, and it is also the fourth CGRP inhibitor drug approved by the FDA.
Migraine is a very common chronic disease. According to statistics from the World Health Organization (WHO), one in ten people in the world suffers from migraine headaches, and migraine is three times more common in women than in men. Patients often occur onset of the disease, symptoms include headaches, sensitivity to light, fear of sound, hallucinations and nausea. At present, the common drug for acute treatment of migraine is triptans. However, these drugs have side effects that cause vasoconstriction.Therefore, patients carrying the risk of cardiovascular disease can not use these drugs.